bioAffinity's Big Bounce: What Really Matters in a Rising Stock bioAffinity Technologies' stock price surged nearly 48% after a reverse split, leaving investors wondering what's behind this sudden jump.
The company's AI powered lung cancer detection technology has shown promise in clinical trials, with an impressive 92% sensitivity and 87% specificity in detecting high risk patients.
However, the real test of bioAffinity's technology lies not in these numbers alone but in whether it can be scaled up to meet growing demand. The financial base is indeed small, with a net loss of $3.